Division of Traffic Medicine, Institute of Forensic Medicine, University of Zurich,
Zurich, ZRH, 8050, Switzerland
Location status: Recruiting
Location contact
Nan Li, MSc
CONTACT
Stefan Lakämper, Dr. rer. nat.
CONTACT
NCT Number: NCT06910605
Attention deficit hyperactivity disorder (ADHD) or syndrome (ADHS) is a symptomatically defined condition that - if untreated - is linked to a significantly increased risk of traffic accidents. In a recent umbrella review, where data from reviews and meta-analyses on 21.142.129 adults was assessed, a pooled prevalence of 3.1% of ADHD in adults was estimated. Considering that globally around 1.35 million people lose their lives and more than 50 million are suffering from injuries or disabilities due to road accidents, the fraction of car accidents caused by ADHD as a risk factor is considerable and needs to be addressed. This risk is largely presumed to be caused by an elevated level of inattentiveness in affected persons.
Compounds of different groups, which can be classified in stimulants - formulations of methylphenidate and amphetamine - and non-stimulants - atomoxetin, guanfacine and clonidine -, have been shown to be effective in alleviating negative effects of ADHD, including inattentiveness. Under well-established but individually managed medication regimes, affected individuals can consequently lead a largely "unirritated" life and are not subject to fundamental restriction with respect to driving anymore.
In children and adolescents, documented negative effects of stimulant medication include loss of appetite and decreased growth rates. It could however be shown that short-term interruptions (weekend, school holidays, and alike), introduced to alleviate aforementioned effects, do not affect the drug's beneficial effects in functional use (e.g., school). Such monitored medication breaks are often called "drug holidays" (D). They have become standard procedure in well-monitored treatment, predominantly including behavioral therapy.
Based on own experience in childhood and or hearsay, also a fraction of affected adults under stimulant medication expresses the desire to take drug holidays and "be themselves" from time to time. With the predominant fraction of medication being fast acting drugs in extended-release formulation and typical patients being not only highly compliant but also extremely informed and adherent, these so-called "drug holidays" are reported an accepted in therapeutically accompanied settings of adults by now.
However, while the overall positive effect of stimulant treatment on driving performance has been confirmed in a row of excellent on road- and/or simulation studies using integrated driving scores (IDS), so far there is no study available addressing the effect of drug holidays in adult drivers on driving performance. This represents a significant gap of evidence for both medical experts and affected.
The proposed study will address this gap by exploring parameters of driving simulation in relation to drug holidays in ADHD patients.
Interested in participating?
Request Info10 year and older
All sexes
Interventional
Not applicable
Zurich, ZRH, 8050, Switzerland
Location status: Recruiting
Nan Li, MSc
CONTACT
Stefan Lakämper, Dr. rer. nat.
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants omit three consecutive daily doses of ADHD-medication (stimulant).
Time frame: 0, x, x+3 days, with x≥ 4 days
Primary outcome parameter IDS (Integrated Driving Score) will be calculated by summation of z-scores of typical driving parameters such as, for example, the standard deviation of lane position (SDLP), standard deviation of velocity (SDS) or number of inappropriate lane departures, ILD. IDS will be measured on day 0 (= baseline, Visit 1), on day x (with x≥4, Visit 2) and on day x+3 (Visit 3).
Contact information is provided by the study sponsor or research team.
Nan Li, MSc
CONTACT
Stefan Lakämper, Dr. rer. nat.
CONTACT
Stefan Lakämper
Other
Acronym: DS-ADHD1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06971640
ADHD, ADHD - Attention Deficit Disorder With Hyperactivity
Durham, North Carolina, United States
View Trial DetailsNCT07281092
ADHD, ADHD - Attention Deficit Disorder With Hyperactivity
Seattle, Washington, United States
View Trial DetailsNCT07089745
ADHD, ADHD - Attention Deficit Disorder With Hyperactivity
Durham, North Carolina, United States
View Trial DetailsNCT07661823
ADHD, ADHD - Attention Deficit Disorder With Hyperactivity
Richmond, Virginia, United States
View Trial Details